Caris Precision Oncology Alliance Welcomes Loma Linda University Cancer Center

Loma Linda University The Cancer Center joins the extensive Caris network of leading oncology institutions committed to using clinical data to advance patient care and outcomes

IRVING, TX, May 5, 2022 /PRNewswire/ –Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced that Loma Linda University Cancer Center (LLU Cancer Center) joined Caris™ Precision Oncology Alliance (POA). POA is a growing network of leading cancer centers around the world collaborating to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve clinical outcomes for cancer patients.

As the largest and most important academic health center and only dedicated cancer center in the Inland Empire region, LLU Cancer Center is committed to cancer prevention, treatment and research, treating high volume and wide patient mix from the southern and eastern regions of California and from the south Nevada. LLU Cancer has been an accredited cancer program by the American College of Surgeons (ACS) Commission on Cancer since 1959 and has been designated a High Performing Site (HPS) by the National Cancer Institute due to the increase important part of the NCI cancer trials.

Loma Linda University The Cancer Center is excited to join the Caris Precision Oncology Alliance and partner with other key academic and clinical institutions that are similarly dedicated to redefining the future of cancer care through research,” said Marc ReevesMD, Ph.D., director, Loma Linda University Cancer Center. “This partnership reinforces our focus on reducing the prevalence and impact of cancers in our community, while strengthening our ability to continue to translate scientific discoveries into cutting-edge cancer care.

A recognized leader in cancer care, LLU Cancer Center was named the 2017 Innovator Award Winner by the Association of Community Cancer Centers and has been an accredited comprehensive cancer center for 35 years. Since 1981, LLU Cancer Center’s highly skilled physicians and caregivers have partnered with cancer patients for world-class care and addressed unique treatment needs, providing accessible and innovative cancer care through through their 11 Centers of Excellence in one convenient hub.

“We are thrilled to welcome LLU Cancer Center as a new member of the growing Precision Oncology Alliance network,” said Chadi Nabhan, MD, MBA, FACP, President of the Caris Precision Oncology Alliance. “Using POA’s shared resources, LLU Cancer Center investigators and researchers will have access to molecular and outcome data that further enhances collaboration and ultimately contributes to better outcomes for all patients diagnosed with cancer.”

The Caris Precision Oncology Alliance includes 63 cancer centers and academic institutions. These institutions have early access to Caris’ extensive database and artificial intelligence platform to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris Molecular Profiling, Caris seeks to provide this network with the ability to prioritize treatment options and identify clinical trial opportunities that may benefit their patients. POA members can also become part of a growing portfolio of biopharma-sponsored biomarker-directed trials. Additionally, as a member of the POA, institutions have access to Caris CODEai™, the industry’s most comprehensive data solution with cancer treatment information and clinical outcome data for more than 275,000 patients spanning over one million data points per patient.

About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (whole exome and whole transcriptome sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris created the Clinico-Genomics Database scale and cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unparalleled resource and the ideal pathway for conducting fundamental basic research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.

With a primary focus on cancer, Caris’ suite of state-of-the-art molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular pattern that helps patients, doctors and researchers better detect, diagnose and treat patients. Caris’ latest advancement, which is currently available within its Precision Oncology Alliance, is a blood-based circulating nucleic acid sequencing (cNAS) assay that combines comprehensive molecular analysis (whole exome and transcriptome sequencing whole from blood) and serial monitoring – making it the most powerful liquid biopsy test ever developed.

Based at Irving, TXCaris has offices in Phoenix, New York, denver, Tokyo, Japan and Basel, Switzerland. Caris provides services across the United States, Europe, Asia and other international markets. To learn more, please visit or follow us on Twitter (@CarisLS).

On Loma Linda University Cancer Center

Loma Linda University Cancer Center is the only dedicated cancer center in the Inland Empire region of Southern California. It houses the first proton therapy hospital center and offers comprehensive cancer care, from prevention to treatment and research. The Cancer Center is part of Loma Linda University Health, a Seventh-day Adventist organization that includes Loma Linda University eight vocational schools, Loma Linda University The six medical center hospitals and more than 1,000 faculty physicians located in the Inland Empire of Southern California.

Caris Life Sciences media contact:

Lisa Burger
[email protected]

Loma Linda University Cancer Center media contact:

Lisa Aubry
Public Relations Specialist
[email protected]

Quote Show original content to download multimedia:

SOURCES Caris Life Sciences

Comments are closed.